Compass Therapeutics (CMPX) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
SAB Biotherapeutics (SABS) has outperformed Compass Therapeutics (CMPX) over the past year, gaining 0.8% versus a loss of 79.8%. Over five years, CMPX leads with a -73.5% price change compared with -97.0% for SABS. SAB Biotherapeutics is the larger company by market cap ($230.2 million vs $154.9 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | SABS |
|---|---|---|
| Share price | $0.86 | $2.53 |
| Market cap | $154.88M | $230.20M |
| 1-day change | -4.09% | -2.32% |
| YTD return | -83.99% | -32.35% |
| 1-year return | -79.81% | +0.80% |
| 5-year return | -73.54% | -97.00% |
| EPS (TTM) | $-0.39 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $0 |
| Revenue growth (YoY) | -100.00% | -100.00% |
| Net income (latest FY) | $-66.49M | $13.27M |
| 52-week high | $6.88 | $5.15 |
| 52-week low | $0.822 | $2.45 |
| Distance from 52-week high | -87.50% | -50.87% |
| Analyst consensus | none | none |
| Avg. price target upside | +533.72% | +360.08% |
| Average volume | 4.30M | 527.29K |
| Shares outstanding | 180.09M | 90.99M |
| Employees | 39 | 86 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SABS has outperformed CMPX by 80.6 percentage points over the past year.
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Healthcare · Biotechnology · 39 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Healthcare · Biotechnology · 86 employees
CMPX vs SABS FAQ
Which is bigger, Compass Therapeutics or SAB Biotherapeutics?
SAB Biotherapeutics (SABS) is larger, with a market capitalization of $230.20M compared with $154.88M for Compass Therapeutics (CMPX).
Which stock has performed better over the past year, CMPX or SABS?
SABS returned +0.80% over the past 12 months, compared with -79.81% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.